Janux Therapeutics heads into its May 8 Q1 print under a cloud of analyst capitulation that has reset price expectations dramatically lower — yet a still-sizeable short position and defensive options skew suggest investors are far from done with the debate.
The sharpest story here is the analyst flight. Barclays downgraded JANX all the way from Overweight to Underweight on April 20, cutting its target from $29 to $14 — right where the stock now trades. UBS followed five days later, dropping from Buy to Neutral and slashing its target from $57 to $15. Together those moves represent a decisive reversal from two firms that were constructive as recently as late 2025. Jones Trading maintained its Buy rating but still cut its target from $50 to $28 on April 28. The consensus price target stands at $44.13, but that figure is dragged higher by older, pre-downgrade targets from Cantor Fitzgerald ($100) and Guggenheim ($68) — views struck after a very different share price trajectory. The analyst community's direction of travel is unmistakably negative.
Options positioning reflects that caution. The put/call ratio has run near the top of its 52-week range, reaching 1.40 against a 20-day average of 1.18, placing it roughly one standard deviation above recent norms. The PCR has climbed steadily since mid-April, shifting from below 0.90 to above 1.40 in a matter of weeks — a pattern that tracks closely with the analyst downgrades and reflects growing demand for downside protection heading into the print.
The bear case, captured in recent clinical data, is pointed. JANX007's interim rPFS of 7.5 months and 50% ORR looked encouraging in isolation, but the company revised market penetration expectations down to 20% and pushed commercial timelines out to mid-2028. The stock fell more than 53% in a single session in December 2025 following an earlier data release — the most severe reaction in its recent earnings history. Since then it has partially stabilised, closing at $14.54 and up 1.2% on the week, but is still down 2.7% over the past month.
Short interest remains substantial but is no longer pressing harder. SI has fallen about 27% over the past month, retreating from nearly 10 million shares short in early April to 7.3 million, now representing 12.1% of the free float. Borrow costs remain low at 0.68% APR despite nearly doubling week-on-week from very depressed levels. Availability is ample, meaning the lending market is not constraining new short positions. Institutional ownership tells its own story: Point72 added 2.1 million shares as recently as April 28, and State Street added nearly 2 million in the most recent period — suggesting some sophisticated money is building exposure even as analysts reduce targets.
Today's print is less about whether JANX007 works in principle and more about whether the updated clinical and commercial parameters can credibly re-anchor the bull case after months of target cuts and a landmark single-session collapse.
See the live data behind this article on ORTEX.
Open JANX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
